HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...

Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today the opening ...

Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome.

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase) is the first drug in the FcRn blocker class to treat CIDP, a rare autoimmune disease of the peripheral nervous system that causes fatigue ...

Argenx (NASDAQ: ARGX) has been upgraded to an "outperform" rating from "underperform" by Bernstein, with the price target revised sharply upwards to €755 from 1 ...

Daniel Cooper, assistant director for blood donation operations, said: “Thanks to our amazing blood and plasma donors in ...

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

The COVID-19 pandemic had a greater effect on the mental health of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) than patients with motor ...

HC Wainwright reaffirmed their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a report issued ...

Guggenheim reiterated their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a report issued on Monday ...

in patients with CIDP. While the exact reasons for a male predominance remain unclear, sex differences in various components of the immune system may contribute to this disparity. “There is marked ...